Disclaimer: We may earn a commission if you make any purchase by clicking our links. Please see our detailed guide here.

Follow us on:

Study says No Serious Health Effects Linked to mRNA Covid Vaccines

Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book.

Join the Opinion Leaders Network

Join the Techgenyz Opinion Leaders Network today and become part of a vibrant community of change-makers. Together, we can create a brighter future by shaping opinions, driving conversations, and transforming ideas into reality.

A team of researchers combining the health records of 6.2 million patients found no serious health effects that could be linked to the Pfizer-BioNTech and Moderna mRNA Covid-19 vaccines.

The study, published in the journal JAMA, indicates mRNA Covid-19 vaccines were not associated with significantly higher rates of 23 serious adverse events.

“These results from our safety surveillance are reassuring,” said lead author Nicola Klein from Kaiser Permanente.

“The world is relying on safe and effective vaccines to bring an end to the Covid-19 pandemic. The Vaccine Safety Datalink is ideally suited to carry out this important surveillance and we will continue to monitor the safety of all vaccines that protect against Covid-19,” Klein added.

The Vaccine Safety Datalink (VSD) is an ongoing collaboration between US health plans and the Centers for Disease Control and Prevention (CDC).

The study reported findings from mid-December 2020 through June 26, 2021.

The analyses compared specific health events among all Covid-19 mRNA-vaccinated people during the first 3 weeks after inoculation with health events among similar types of patients during the 3 to 6 weeks after mRNA vaccination.

The total number of people evaluated was 6.2 million for the first dose of either mRNA vaccine and 5.7 million for the second dose.

The authors added a comparison group of unvaccinated patients in a supplemental analysis.

The researchers examined 23 potential health effects, chosen because they had been included in previous vaccine studies, were of particular concern as an effect of Covid-19, were noted during the Covid-19 clinical trials, or were added after public health officials reported increased cases among vaccinated people.

Outcomes tracked included neurological disorders such as encephalitis, myelitis, seizures, and Guillain-Barre syndrome; cardiovascular problems such as acute myocardial infarction, stroke, and pulmonary embolism; and Bell’s palsy, appendicitis, anaphylaxis, and multisystem inflammatory syndrome.

Patient medical records were searched electronically and analysts carried out chart reviews of specific health outcomes to verify the medical problem and to assess whether it started before or after vaccination.

The study authors highlighted their findings of cases of confirmed myocarditis and pericarditis among young individuals, as that has become an outcome of concern.

The VSD study identified 34 cases in patients 12 to 39 years old; 85 percent were male and 82 percent hospitalized (for a median of 1 day), and nearly all recovered by the time the chart review took place.

Partner With Us

Digital advertising offers a way for your business to reach out and make much-needed connections with your audience in a meaningful way. Advertising on Techgenyz will help you build brand awareness, increase website traffic, generate qualified leads, and grow your business.

Join 10,000+ Fellow Readers

Get Techgenyz’s roundup delivered to your inbox curated with the most important for you that keeps you updated about the future tech, mobile, space, gaming, business and more.


Find Apps

The Ultimate Hub for Discovering Apps Unlock a world of apps: your ultimate hub for exploring and discovering limitless possibilities for on your every needs.

Power Your Business

Solutions you need to super charge your business and drive growth

More from this topic